aTyr flunks phase 3 lung disease trial, deflating stock, but still plans talks with FDA
A phase 3 trial of aTyr Pharma’s efzofitimod in a lung disease has missed its primary endpoint. With a multibillion-dollar market in its sights, the biotech is planning to talk…